

Research Article

A PROSPECTIVE STUDY ON THE EFFICACY OF CISPLATIN AND ETOPOSIDE COMBINATION CHEMOTHERAPY IN PATIENTS WITH MALIGNANT GONADAL GERM CELL TUMORS

*Sudha, R., Navajothi, R. and Muthukumarasamy, P.K.

Kapv. Govt. Medical College, Tiruchirappalli, TamilNadu, India

ARTICLE INFO

Article History:

Received 19th, September 2015
Received in revised form
07th, October 2015
Accepted 24th, November 2015
Published online 30th, December 2015

Keywords:

α FP,
 β HCG

ABSTRACT

Malignant gonadal germ cell tumors are the rare malignant tumors .It occurs in young individuals at the peak of their reproductive life between 18- 45yrs. First line therapy with three and four drugs regimen increases the survival of 80-90% with increased drug induced toxicity. Two drug regimen with cisplatin and etoposide results in improved survival rate with reduced drug induced morbidity. The study was carried out in a tertiary care hospital for a period of 21 months. Twenty six patients were selected and six patients were excluded. Prior to treatment all patients were evaluated with basic investigations. α FP and β HCG were estimated before and after chemotherapy. Cisplatin 20mg /m² and Etoposide 75mg/m² was given daily for five consecutive days at an interval of 21 days in four cycles. patients were observed for adverse effects during the course of therapy. Response was evaluated by evidence of regression of the documented tumors and measuring serum tumor markers level .In this study 85% of patients were responded completely to the treatment and side effects were also less during chemotherapy and the follow up period. 5% were partial responders and 10% were non responders. They were recommended for alternative therapy.

Copyright © 2015 Sudha et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

INTRODUCTION

Germ cell tumors are rare malignant neoplasm. They classified into gonadal and nongonadal germ cell tumors. Gonadal germ cell tumors include both testicular and ovarian germ cell tumors. They commonly occur in young individuals between 15-45 years. Germ cell tumors are associated with two tumor markers: alpha fetoprotein (AFP) and beta human chorionic gonadotropin (B HCG). The levels of these two serum tumor marker are linked to the volume of metastatic disease and thus provide reliable information about the prognosis of treatment (Horwich, 1987). Germ cell tumors are sensitive to chemotherapy as well as radiotherapy. Early germ cell tumors can be treated with radiotherapy and surgery. When the neoplasm is locally advanced or when there is lymphnode metastasis it requires surgery followed by chemotherapy. In the early 1960s, germ cell tumors were treated with a single drug, usually vinblastin alone. This agent was able to induce complete remission in 4 of 30 treated patients (Samuels *et al.*, 1975). Subsequently combination regimens, Cisplatin, Vinblastin and bleomycin (PVB) and Cisplatin, Vinblastin, bleomycin, dactinomycin and cyclo phosphamide (VAB-6) were introduced. These combinations improved the survival of 80-90% of the treated patients (Vugrin *et al.*, 1983).

Although most patients were cured, they experienced chemotherapy related mortality and morbidity. To minimize these toxicities two drug therapy with cisplatin and etoposide was introduced. The present study aims at evaluating the efficacy of this two drug regimen (Cisplatin & etoposide) in patients with both testicular and ovarian germ cell tumors. The effects were correlated with serum tumor marker levels and also by the evidence of distant metastasis.

MATERIALS AND METHODS

The study was carried out in the Department of Medical Oncology, Government Rajaji Hospital, Madurai, after obtaining approval from the Institutional ethics committee and with the informed consent of the patients. Only those patients with histopathologically confirmed malignant gonadal germ cell tumor with either Measurable disease after primary surgery or loco regionally advanced disease with or without distant metastasis were included in this study. Extensive prior treatment with several chemotherapy regimens (Since these patients might have had recurrent relapses), Performance status score of 60 or less in the karnofsky performance status scoring system (Table 1) impaired renal or hepatic function, Impaired bone marrow function with anemia (Hb<9gm), leucopenia (WBC<4,000) and thrombocytopenia (platelets < 1,00,000) and H/O allergy/drug intolerance were excluded from the study.

*Corresponding author: Sudha, R.,
Kapv. Govt. Medical College, Tiruchirappalli, TamilNadu, India.

Table 1. Karnofsky Performance Status Index (Mor. V. et al 1984)

General Category	Index	Specific Criteria
Able to carry on normal activity, no special care needed	100	Normal, no complaints, no evidence of disease.
	90	Able to carry on normal activity, minor signs or symptoms of disease.
	80	Normal activity with effort, some signs or symptoms of disease.
Unable to work, able to live at home and care for most personal needs. Varying amount of assistance needed.	70	Able to care for self, unable to carry on normal activity or do work.
	60	Requires occasional assistance from others.
	50	Frequent medical care
Unable to care for self, requires institutional or hospital care or equivalent, disease may be rapidly progressing	40	Disabled requires special care and assistance.
	30	Severely disabled, hospitalization indicated; death not imminent.
	20	Very sick, hospitalization necessary; active supportive treatment necessary.
	10	Moribund
	0	Dead

Pretreatment evaluation

Twenty six patients were selected, due to irregular follow up six patients were excluded from this study. The selected patients were evaluated for performance status, presence/absence of organ dysfunction. History and Clinical evaluation done thoroughly. They were

all investigated for complete hemogram, urinary bile pigments, urea, creatinine, fasting blood glucose, serum bilirubin, SGOT, SGPT and serum alkaline phosphatase, Chest X ray PA view, Ultrasonography of abdomen and pelvis, serum tumor markers β HCG and α FP, CT scan of thorax, abdomen, brain if indicated by symptoms / signs.

Study design

All the selected patients were given cisplatin (20mg/m²) dissolved in 1 pint of 5 percent dextrose. It was given as slow intravenous infusion for 3hours. This was immediately followed by infusion of etoposide (75mg/m²) dissolved in 1 pint of normal saline and was given as saline intravenous infusion.

They were given Inj. Dexamethasone 16mg IV and Inj. Ondansetron 8mg IV 8th hrly. On the day of administration the patients were carefully observed for adverse effects. During the 15 days interval between two successive cycles, patients were discharged and permitted to stay at home. They were instructed to report any adverse events immediately, particularly the occurrence of fever, diarrhoea, dysentery, oral ulcers, jaundice and breathlessness.

Evaluation of response

The response to treatment with cisplatin and etoposide combination was evaluated by evidence of regression of the documented tumors as revealed by ultrasonography, chest x-ray and other imaging modalities as recorded and estimating the tumor markers α FP and B HCG before 1st cycle and at the end of the 4th cycle. The response to chemotherapy is quantified as complete response, partial response and no response. At the end 4th cycle complete responders were reevaluated and discontinued from the treatment. Partial and non responders were offered alternative treatment.

RESULTS

20 patients with various forms of gonadal germ cell tumors were enrolled in this study

In seminoma and dysgerminoma, the tumor markers are usually absent due to the absence of trophoblast, were evaluated directly by the measured regression of the initially documented tumor masses or secondaries in the para aortic lymphnode /liver/ lungs as appropriate.

Table 2. The detail about the number of patients with the relevance to the various types of tumors is given

Malignant gonadal germ cell tumors	Number of patients
Testicular germ cell tumor	0
Seminoma	4
Embryonal carcinoma	1
Malignant teratoma	1
Yolk sac tumor	1
Mixed germ cell tumor	3
Ovarian germ cell tumor	
Dysgerminoma	2
Malignant teratoma	2
Endodermal Sinus tumor	3
Mixed germ cell tumor	3

The nonseminomatous and nondysgerminomatous tumors, tumor markers (α FP and β HCG) are often secreted and are measurable in the serum. Hence the response to chemotherapy can be evaluated in these tumors indirectly by estimating the serum tumor markers, as also directly by the measured regression of initially documented tumor masses.

Marker status at presentation

Table 3. Testicular germ cell tumors-marker status

Tumor	Number	Number		
		I	II	III
Seminoma	4	0/4	3/4	1/4
			AFP (-)	AFP (-)
Embryonal Carcinoma	1	0/1	1/1	0/1
			AFP>529	HCG<200
Malignant Teratoma	1	0/1	1/1	0/1
			AFP<200	HCG<200
Yolk Sac Tumor	1	0/1	0/1	1/1
Mixed germ Cell tumor	3	0/3	0/3	3/3
				AFP<200-2
				>529 -1
				HCG<200 -1
				>653 -2

Serum tumor markers (AFP, HCG) level were estimated before and after chemotherapy in non seminomatous and nondysgerminomatous tumors.

Table 4. Ovarian germ cell tumors-marker status

Tumor	Number	Stage			
		I	II	III	IV
Dysgerminoma	2	0/2	2/2 AFP (-) HCG (-)	0/2	0/2
Malignant Teratoma	2	0/2	2/2 AFP<200-1 <529-1 HCG<200-1 <400-1	0/2	0/2
Yolk Sac Tumor	3	0/3	2/3 AFP<400-1 <529-1	1/3 AFP<400-1	0/3
Mixed germ cell	3	0/3	1/3 AFP<529-1 HCG<200-1	2/3 AFP<529-1 >529-1 HCG>200-1 >400-1	0/3

After chemotherapy the serum markers level reduced significantly (P < 0.05). Non responders the tumor marker level reduced partially. The results are depicted in figures 1&2.




Fig. 1. Alpha Fetoprotein




Fig. 2. Beta Hcg




Fig. 3. Total Response to Chemotherapy

85% of patients were responded well to the treatment and there was no significant side effects during the follow up period. Partial responders and non responders were offered alternative treatment.

Toxicity Profile

Total Cycles administrated 80

Absolute neutrophil Count < 1000 at the end of Chemotherapy cycle 0/80

Adverse effects	Results
Nadir neutropenia	< 1000 7/80 <50 0/80
Nadir thrombocytopenia	<50,000 2/80, <20000 0/80
Nausea/ Vomiting	Mild 63/80 Moderate 12/80 Severe 5/80
Mucositis	Gr I 7/80 Gr II 0/80 Gr III/IV 0/80
Total Alopecia	100%
Hyper pigmentation	palms & nails 100%
Tetany	0
Arterial Occlusion	0
Peripheral neuropathy	3/20 (15%)

There was no chemotherapy related mortality reported during the study period.

DISCUSSION

Germ cell tumors are highly curable neoplasms. Early detection and treatment results in 5 year disease free survival of greater than 95% and also preserves fertility which is an important issue for a young individual (Gershenson and Wharton, 1985). Combination chemotherapy increases the drug related toxicity. In the present study, combination of cisplatin and etoposide is most often preferred for the first line treatment of malignant germ cell tumors of testis and ovary. This combination is less toxic, but at the same time does not diminish the response rate and survival duration.

Worldwide many randomized clinical trials on cisplatin and etoposide combination chemotherapy have been conducted in patients with malignant gonadal germ cell tumors. The reports revealed complete response rate of 88-93% in patients with stage 1 and stage II (Bajorin, 1993; Bosl, 1986; Mann, 1989; Stoter and Kaye, 1990). Hence cisplatin and etoposide combination chemotherapy has been accepted as a standard regimen for stage I and stage II malignant testicular germ cell tumors.

Regarding ovarian germ cell tumors, the incidence is very rare. The occurrence of ovarian germ cell tumor is only one tenth of testicular germ cell tumors. Because of the rarity, randomized studies have not been conducted in ovarian germ cell tumors. Chemotherapy trials results obtained from testicular germ cell tumors have been applied to the ovarian germ cell tumors (Loehrer, 1995; Lalit kumar, 1999; Motzer, 1995).

In the present study complete responders were on regular follow up, there was no evidence of relapse during the mean follow up period of 8 months. Partial responders were recommended for alternative therapy. Non responders were stage III patients with distant metastasis. Post chemotherapy evaluation in these patients revealed marked elevation of the tumor markers and progression of distant metastasis.

These patients were also offered for four drug combination chemotherapy.

Conclusion

Malignant gonadal germ cell tumors are highly curable neoplasm in early stage. They commonly occurs in young individuals at their peak of productive age. Recently the incidence is found to increased in developed countries and also in HIV positive men (Wilkinson and Carroll, 1990). These factors focus the early detection and management of malignant gonadal germ cell tumors. Our study also revealed high response rate in stage I and stageII with less drug induced toxicity. The efficacy is almost equal with trails conducted earlier. However our study needs long term follow up to find out the occurrence of relapse and disease free survival.

REFERENCES

- Bajorin, D.F. *et al.* 1993. Two drug therapy in patients with metastatic germ cell tumors. *Cancer*, 67:28.
- Bosl. C.J. *et al.* 1986. A randomized trial of Etoposide +cisplatin versus vinblastin + bleomycin + cisplatin +cyclophosphamide +dactinomycin in patients with good prognosis germ cell tumors. *J.clin.oncol*, 6:1231.
- Gershenson, DM., Wharton, Jt., 1985. Malignant germ cell tumors of the ovary. In ovarian cancer Edited by DS Albert, EA Jurwit. Hingham, MA: Martinus Nijhoff 227- 269.
- Horwich A. *et al.* 1987. Prognosis following combination chemotherapy for metastatic malignant teratoma.*Br.J.Urol.*,59:578-583.
- Lalit kumar *et al.* 1999. Malignant germ cell tumors of ovary , Current trends in gynecologic oncology, pages 100-110.
- Loehrer, PJ., *et al.* 1995. Importance of bleomycin in favourable prognosis disseminated germ cell tumors: an Eastern cooperative oncology group trial. *Clin. Oncol.*, 13:470.
- Mann, J.R. *et al.* 1989. Results of united kingdom children cancer study groups malignant germ cell tumor studies. *Cancer* ,63:1657 -1667.
- Mor, V. *et al.* 1984. The kornosfsky Performance status scale:an examination of its reliability and validity in a research setting.*Cancer.*,53:2002.
- Motzer, R.J. *et al.* 1995. Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumor. *Clin.oncol.*, 13: 2700.
- Samuels.M., Holoye P. and Johnson D. 1975. Bleomycin combination chemotherapy in the agent of testicular neoplasia.*Cancer*, 36:318-326.
- Stoter, G. and Kaye, S.B. 1990. Prognostic factors and treatment options in disseminated nonseminomatous testicular cancer. International testicular and prostate cancer conference , Toronto,Canada.40.
- Vugrin, D. *et al.* 1983. VAB-6 combination chemotherapy in treatment of disseminated cancer of the testis. *Cancer*, 51:211-215.
- Wilkinson, M. and Carroll, P.R. 1990. Testicular carcinoma in patients positive and at risk for human immunodeficiency virus. *J.Urol.*, 144 :1157 – 1159.
